Understanding Treatment Tolerability in Older Adults With Cancer
Marie Flannery, Eva Culakova, Beverly Canin, Luke J. Peppone, Erika Ramsdale, Supriya G. Mohile
Abstract
Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00195 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043433 Understanding Treatment Tolerability in Older Adults With Cancer Marie A. Flannery , PhD, RN1xMarie A. FlannerySearch for articles by this author; Eva Culakova , PhD2xEva CulakovaSearch for articles by this author; Beverly E. Canin 3xBeverly E. CaninSearch for articles by this author; Luke Peppone , PhD2xLuke PepponeSearch for articles by this author; Erika Ramsdale , MD4xErika RamsdaleSearch for articles by this author; and Supriya G. Mohile, MD, MS4xSupriya G. MohileSearch for articles by this author Show More 1University of Rochester Medical Center, School of Nursing, Rochester, NY2Department of Surgery, University of Rochester Medical Center, Rochester, NY3SCOREboard Stakeholder Advisory Group, University of Rochester Medical Center, Rochester, NY4Department of Medicine, University of Rochester, Rochester, NY https://doi.org/10.1200/JCO.21.00195 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveWhat do we know about cancer treatment tolerability in older adults and where are the gaps?Knowledge GeneratedAlthough there is strong evidence that geriatric assessment findings can be helpful in predicting treatment tolerability in older adults with cancer, more research is needed on treatment tolerability assessment, monitoring, and mitigation efforts for older adults during and after completion of treatment. A model is proposed to guide research efforts and clinical care that incorporates multiple tolerability aspects and highlights the patient's experience and functional status as important end points.RelevanceIncorporating patient-reported outcomes, functional evaluation, and adverse event data provides a more comprehensive and accurate understanding of treatment tolerability in older adults.SUPPORTSupported by National Cancer Institute at the National Institutes of Health (Grant Nos UG1 CA189961, R01 CA177592, and U01CA233167) and National Institutes on Aging (Grant Nos R33 AG059206 and K24 AG056589).AUTHOR CONTRIBUTIONSConception and design: All authorsAdministrative support: Supriya G. MohileFinancial support: Supriya G. MohileCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTUnderstanding Treatment Tolerability in Older Adults With CancerThe following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Luke PepponeConsulting or Advisory Role: Charlotte's WebSupriya G. MohileConsulting or Advisory Role: Seattle GeneticsResearch Funding: CareviveNo other potential conflicts of interest were reported.